Page last updated: 2024-11-08

n(6),n(6)-dimethyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6),N(6)-dimethyladenosine : A methyladenosine compound with two methyl groups attached to N(6) of the adenine nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID440004
CHEMBL ID1229848
CHEBI ID28284
SCHEMBL ID157530
MeSH IDM0075422

Synonyms (45)

Synonym
CHEMBL1229848
6n-dimethyladenosine
26A ,
6-dimethylaminopurine 9-riboside
(2r,3r,4s,5r)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
2620-62-4
n6,n6-dimethyladenosine
C03416 ,
6-(dimethylamino)purine riboside
CHEBI:28284 ,
n,n-dimethyladenosine
n6-dimethyladenosine
6-(dimethylamino)purine ribonucleoside
6-dimethylaminopurine d-riboside
n(6),n(6)-dimethyladenosine
6-dimethyladenosine
6-n-dimethyladenosine
(2r,3r,4s,5r)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
0l9766ew9w ,
nsc 627046
6-(gamma,gamma-dimethylamino)purine riboside
6-dimethylaminopurine riboside
unii-0l9766ew9w
einecs 220-057-7
EPITOPE ID:140944
S12121
SCHEMBL157530
6-dimethylaminopurine-9-riboside
(2r,3r,4s,5r)-2-(6-(dimethylamino)purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
j108.278g ,
n,n-dimethyl-9-.beta.-d-ribofuranosyl-9h-purine-6-amine
adenosine,n,n-dimethyl-
AKOS027327106
(2r,3r,4s,5r)-2-(6-(dimethylamino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6-(dimethylamino)purineribonucleoside
mfcd00022822
Q15632696
HY-101984
CS-0022419
DTXSID90949075
n,n-dimethyl-9-pentofuranosyl-9h-purin-6-amine
A902102
(2r,3r,4s,5r)-2-(6-(dimethylamino)-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
6-dimethylamino-9-(beta-d-ribofuranosyl)purine
BS-27732
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydrocarbyladenosine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (73.68)18.7374
1990's1 (5.26)18.2507
2000's1 (5.26)29.6817
2010's2 (10.53)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]